A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention (Q44244531)

1 December 2017

A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention (English)

1 reference

1 December 2017

2

Gilles Montalescot

1 reference

1 December 2017

7

Gérard Drobinski

1 reference

1 December 2017

1

Rémi Choussat

1 reference

1 December 2017

3

Jean Philippe Collet

1 reference

1 December 2017

Eric Vicaut

4

1 reference

1 December 2017

Annick Ankri

5

1 reference

1 December 2017

Vanessa Gallois

6

1 reference

1 December 2017

Ivan Sotirov

8

1 reference

1 December 2017

Daniel Thomas

9

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Journal of the American College of Cardiology

1 December 2017

1 reference

1 December 2017

40

1 reference

1 December 2017

11

1 reference

1 December 2017

1943-1950

1 reference

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Antithrombotic therapy in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Safety of low dose heparin in elective coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Minimal heparinization in coronary angioplasty—how much heparin is really warranted?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Dalteparin in combination with abciximab during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Predictors of groin complications after balloon and new-device coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Enoxaparin in unstable angina patients with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, E

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Low molecular weight heparins in the cardiac catheterization laboratory

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902531-7

7 January 2021

10.1016/S0735-1097(02)02531-7

Identifiers

DOI

1 reference

1 December 2017

1 reference